PMC21 ASSESSING THE RELATIONSHIP BETWEEN COMPUTATIONAL SPEED AND PRECISION: A CASE STUDY USING A DISCRETE EVENT SIMULATION MODEL IN DIABETES CARE  by Gordon, JP et al.
designed to support both the collection of PRO data and the
development of an economic model.
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OBJECTIVES: Behavioral health interventions traditionally use
a simple dichotomous outcome criterion: ‘success’ or ‘failure’.
In reality, though, behavior change is a complex process in
which several steps towards success are taken. There has been
little consideration, however, about whether future behavior
change should be incorporated in cost-effectiveness analyses
(CEAs). The aim of the present review is to identify and evalu-
ate the usage of cognitive, intermediate outcomes in CEAs of
behavioral interventions. METHODS: Electronic data sources
(PsycInfo, WebofScience, Medline, ScienceDirect and Scopus)
were searched for CEAs published before February 2008.
RESULTS: Most CEAs and CUAs reporting cognitive, interme-
diate outcomes of behavior change fail to incorporate partial
behavior changes. Only nine studies were eligible for inclusion
in this review. Smith et al 2007 [1] conducted the only study in
which partial behavior change was incorporated in the ﬁnal
outcome by modeling cognitive, intermediate outcomes: the
stages of change, derived from the Transtheoretical model
(TTM). The TTM is a stage-oriented model that describes the
process by which a change in behavior takes place. It describes
the readiness to change and the processes employed by indi-
viduals to achieve behavioral change. With inclusion of future
behavior change, Smith et al showed that the incremental cost-
effectiveness ratio declined compared to the standard analysis.
CONCLUSIONS: The results suggest that CEAs of behavioral
interventions can be further optimized by the measurement of
intermediate outcomes and use these to determine partial
behavior change at the end of an intervention period as well. In
other words, when partial behavior change and relapse rates
are incorporated in CEAs of behavioral treatments, a more
realistic and transparent ﬁnal outcome can be calculated. [1]
Smith, MY, Cromwell, J, DePue, J, et al. Determining the cost-
effectiveness of a computer-based smoking cessation interven-
tion in primary care. Managed Care 2007;16:48–55.
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OBJECTIVES: To develop a quantitative model that can deter-
mine the effect of segmentation and positioning on revenue
generation based on different variables, health economic consid-
erations and pricing scenarios, creating a tool which is easy to use
for the ﬁrst evaluation of options. METHODS: Literature review
and interviews with industry experts were conducted followed by
the development of qualitative framework, logic and the subse-
quently a quantitative model. The model was tested and vali-
dated using real life examples. RESULTS: A qualitative model
was developed which presents an iterative strategy to align stake-
holders’ interest with different scenarios of segmentation. From a
given asset base of active ingredients, the pharmaceutical
company deﬁnes therapeutic areas for a component and deter-
mines segments within them, evaluating both attractiveness and
speciﬁc propositions for patients, payers and prescribers in com-
prehensive scenarios. For the payer’s perspective in particular,
health economic beneﬁts of the proposed segmentation approach
must be contemplated. Following this analysis, objectives and
strategies for the chosen segments are developed and a holistic
value proposition can be delivered to the market. Ideally, the
process should be initiated early during development in order to
design clinical trials according to the segmentation strategy. The
process should also be monitored throughout the marketing and
sales process in order to make improvements, and to react to
changes in health care policies or the competitive landscape.
Following the qualitative analysis, a quantitative model was
developed in Excel that captures the effect of multiple variables
such as age, gender, disease severity, co-morbidities, insurance
type and multiple price points on revenue generation, positioning
and pricing of pharmaceuticals. The model was tested and vali-
dated using the example of bipolar disorder (BPD) in women
with childbearing potential. A new product with lower teratoge-
nic risks was evaluated along different segmentation scenarios in
order to determine improved overall cost-effectiveness when
compared to conventional treatments. CONCLUSIONS: Seg-
mentation is an important tool that could lead to better revenue
generation from the company’s perspective and is accepted posi-
tively by payers due to optimized budget impact with better
health outcomes.
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BACKGROUND: In model-based health economic evaluations,
to achieve a given level of precision surrounding modelled
outputs there is a trade-off between treatment effect estimates
and the computational time associated with the programming
format used to ‘code’ the model. OBJECTIVES: To explore the
relationship between modelled effect size, statistical precision
and the computational time associated with two commonly used
programming frameworks. METHODS: A published and vali-
dated cost-utility discrete event simulation (DES) diabetes model
(Cardiff model) was programmed in MS Excel with Visual Basic
(VB), and more recently reprogrammed in C as with other
models in this area, to illustrate the efﬁciency gains in terms of
computational speed achieved under different programming
frameworks. A treatment effect of 0.4% HbA1c improvement
was applied to a mean cohort proﬁle of 10,000 patients; preci-
sion in the predicted number of clinical events was used to assess
relative efﬁciency of VB and C. RESULTS: In the C programmed
model in order to show a signiﬁcant difference at the 95% level
in the predicted number of events in the control and treatment
arms required 50 iterations of the model using mean values. This
equated to a model run time of 1 minute. The equivalent number
of iterations in VB took 133 minutes to demonstrate a signiﬁcant
difference in the predicted number of events. Typically, one-way
sensitivity analysis using this model to explore 40 scenarios
would equate to a run time of 40 minutes in C and 5,320 minutes
(88.7 hours) in VB. CONCLUSIONS: Programming format can
impact the computational time associated with running the
model with subsequent practical implications for the usability of
the model. We conclude that with reasonably complex models,
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more computationally efﬁcient programming languages (such as
C) are preferred; concerns regarding model transparency using
compiled languages are best addressed via thorough documenta-
tion and model testing.
CONCEPTUAL PAPERS & RESEARCH ON METHODS—
Patient-Reported Outcomes Studies
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OBJECTIVES: Gains in life expectancy have lead to aging popu-
lations with more chronic comorbidity. This study aims to
examine the impact of age and comorbidity on EQ-5D index
scores in a nationally representative sample of the U.S.
METHODS: The pooled 2001 and 2003 Medical Expenditure
Panel Survey (MEPS) was used. MEPS is a nationally represen-
tative survey of the U.S. civilian, noninstitutionalized population
based on self-report which collects detailed information on socio-
demographic characteristics, medical conditions and HRQL. The
total number of chronic conditions for each individual was cal-
culated based on ICD-9 codes. Spline regression was used to
allow for nonlinear age effects: individuals were separated into 4
quartiles based on age: 18–31; 32–44; 45–58; and >58 years.
Censored least absolute deviations (CLAD), Tobit and OLS
methods were used to regress EQ-5D index scores on age and
chronic comorbidity, controlling for income, gender, race, eth-
nicity, education, physical activity and smoking status. Interac-
tions between age and chronic conditions were also explored.
RESULTS: After controlling for chronic comorbidities and other
confounders, age was not statistically signiﬁcant except for those
>58 years and the magnitude of this coefﬁcient was very small
(coefﬁcient age >58 years = -0.0006). However, the coefﬁcients
for chronic comorbidities were highly statistically signiﬁcant
with large magnitudes for those with 2 chronic conditions
(coefﬁcient 2 chronic conditions = -0.16; coefﬁcient 9 chronic
conditions = -0.28). Having only one chronic condition was not
statistically signiﬁcant. The interaction between age and chronic
comorbidity was signiﬁcant, but the deleterious impact of their
interaction was largely dominated by the existence and number
of chronic conditions. CONCLUSIONS: Chronic conditions
have a signiﬁcant deleterious impact on EQ-5D index scores
regardless of age. The negative impact of age on EQ-5D
index scores may be due to the existence and degree of chronic
comorbidity.
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OBJECTIVES: To estimate WTP (€, 2006 value) per incremental
quality-adjusted life-year (QALY) gained for a future health tech-
nology when compared to the current technology in the treat-
ment of a particular disease. Secondly, WTP for incremental
life-year gained (LYG), and WTP for average QALY and LY were
estimated. METHODS: For the ﬁrst time in the Finnish setting,
CV was used to establish WTP for health beneﬁts that do not
have market prices. A postal survey including 8 diseases (1092
cases in total) with dichotomous choice (DC) type questions was
carried out to clinicians (N 197) and political decision makers (N
225). Based on the answers with varying costs for health beneﬁt,
aggregate demand functions (ADF) were drawn and the mean
WTP for particular beneﬁt in particular disease was estimated as
the area under ADF. As a new innovation, the potential future
order of disease priority in terms of WTP was established by
estimating cumulative marginal changes (CMC) in ADF. The care
costs and utilities were obtained from recent Finnish literature.
Discounting with 5% and 0% was done due to the life-time
perspectives. RESULTS: The mean WTP per incremental QALY
gained with 15D/EQ-5D utilities were the following (CMCs are
in the parentheses): neurological disturbance €420,921/46,8004
(€147,653/164,168), metabolic disturbance €320,974/333,961
(€118,823/123,631), cancer €127,937/138,308 (€61,611/
66,604), dementia €100,536/107,731 (€40,830/43,731),
paraplegia €124,544/563,41 (€35,013/15,839), coronary heart
disease €48,381/50,928 (€15,191/15,989), type 1 diabetes
€107,114/548,63 (€19,989/10,238), and narcomaniac €30,859/
45,106 (€7,705/14,231). WTPs for incremental LYG, average
QALY and LY were lower. The difference between EQ-5D and
15D WTP exceeded 10% in paraplegia, diabetes, narcomaniacs,
and neurological disease. This demonstrated that the results
obtained using different utility tools differ even in the ADF-
setting. CONCLUSIONS: Depending on the disease and utility
tool, CV based on DCs seems to result to different ADFs and
WTPs. By estimating CMCs from ADFs, potential future order
for diseases is estimated.
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No population norms for any generic health related quality of life
questionnaire are currently available in Poland. OBJECTIVES:
To measure the health of a representative sample of the general
population of Poland by using EuroQol questionnaire.
METHODS: Visitors of patients in seven medical centers in
Warsaw, Skierniewice and Pulawy, aged 18 and over, were inter-
viewed during Polish EQ-5D valuation study. Stratiﬁed quota
sampling was used. Respondents completed EQ-5D question-
naire and provided information on age, sex, marital state, edu-
cation, employment, income, housing tenure, medical history
and smoking behaviour. The interviews took place since Febru-
ary till May 2008. RESULTS: The ﬁnal sample comprising 317
subjects (62% Warsaw residents) was representative of the
general population with respect to age and sex. A moderate
problem on at least one dimension was reported by 57% respon-
dents, whereas only 4.7% of respondents reported any extreme
problem. Forty percent of respondents reported any problems
with pain or discomfort, 38% with anxiety or depression, 16%
with mobility, 13% with usual activities and 3% with self care.
The mean state of health recorded on the visual analogue scale
was 81.6 (SD 14.4). The mean VAS value decreased from about
87 and 91 in the youngest age group to 67 and 72 in the oldest
age group, in men and women respectively. CONCLUSIONS:
Pain and anxiety are commonly reported in Polish society.
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